Johnson & Johnson is set to report its Q2 2026 earnings with analysts expecting earnings per share of $2.85 and revenue of $25.02 billion, both higher than the previous year. The company has a strong track record of beating revenue estimates and its stock has risen over 20% this year, reaching an all-time high of $269 per share. Analysts have raised price targets, reflecting confidence in the company’s growth and solid financial health, including a trailing P/E ratio of 29.28 and a debt-to-equity ratio of 0.68. This stable performance highlights Johnson & Johnson’s defensive qualities despite challenges like patent expirations.
Johnson & Johnson and AbbVie both posted strong quarterly results but differ in dividend approach and business focus. J&J, a Dividend King with 64 years of raises, offers a modest 2.02% yield supported by diversified pharma and MedTech products. AbbV...
The iShares Core High Dividend ETF (HDV) relies heavily on energy and pharmaceutical sectors, with Exxon Mobil, Chevron, Johnson & Johnson, and AbbVie making up about 26% of its assets. Exxon and Johnson & Johnson are rated very safe due to strong ca...
Revolution Medicines closed at $205.55 on August 11, 2026, reaching a $44.1 billion market cap driven by its promising RAS-targeting oncology pipeline. The company has no current product revenue but shows strong clinical results, especially with dara...
Invesco's High Yield Equity Dividend Achievers ETF (PEY) uses a unique strategy by selecting stocks with at least 10 years of consecutive dividend growth before filtering for high yield. This approach avoids the pitfalls of pure yield-based ETFs that...
Johnson & Johnson shares trade near their 52-week high after a 55% rise, driven by strong revenue growth and promising drug sales. The company raised its full-year guidance, highlighting growth in key products like DARZALEX and TREMFYA. However, the ...
